Related Experiment Videos
In vitro activity of U-76,252 (CS-807), a new oral cephalosporin
1Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210.
Abstract:
U-76,252 is the prodrug of U-76,253. MICs of U-76,253 were 0.015 to 0.06 microgram/ml for greater than or equal to 90% of the strains of Streptococcus spp., Haemophilus influenzae, and Proteus mirabilis; 0.25 to 1 microgram/ml for Branhamella catarrhalis, Escherichia coli, Klebsiella spp., and Citrobacter diversus; 1 to 8 micrograms/ml for Staphylococcus spp.; and 2 to greater than 16 micrograms/ml for other members of the family Enterobacteriaceae and Aeromonas hydrophila; for 72% of the latter group, MICs were less than or equal to 4 micrograms/ml. MICs for Pseudomonas aeruginosa and Enterococcus faecalis were greater than 16 micrograms/ml.
Insights
U-76,253, the active form of U-76,252, demonstrates potent antimicrobial activity against key respiratory pathogens like Streptococcus spp. and Haemophilus influenzae. Its efficacy varies across bacterial species, with higher minimum inhibitory concentrations (MICs) observed for Pseudomonas aeruginosa and Enterococcus faecalis.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- U-76,252 is a prodrug, meaning it is converted into its active form, U-76,253, within the body.
- Understanding the antimicrobial spectrum and potency of U-76,253 is crucial for evaluating its therapeutic potential.
Purpose of the Study:
- To determine the in vitro antimicrobial activity of U-76,253 against a range of clinically relevant bacterial species.
- To establish the minimum inhibitory concentrations (MICs) of U-76,253 for various Gram-positive and Gram-negative bacteria.
Main Methods:
- Minimum Inhibitory Concentrations (MICs) were determined for U-76,253 against multiple bacterial strains.
- Standard microbiological techniques were employed to assess bacterial susceptibility.
Main Results:
- U-76,253 exhibited potent activity (MICs 0.015–0.06 µg/ml) against Streptococcus spp., Haemophilus influenzae, and Proteus mirabilis.
- Moderate activity was observed against Branhamella catarrhalis, Escherichia coli, Klebsiella spp., and Citrobacter diversus (MICs 0.25–1 µg/ml).
- Lower activity was noted against Staphylococcus spp. (MICs 1–8 µg/ml) and other Enterobacteriaceae/Aeromonas hydrophila (MICs 2–>16 µg/ml), with 72% having MICs ≤4 µg/ml. Pseudomonas aeruginosa and Enterococcus faecalis showed resistance (MICs >16 µg/ml).
Conclusions:
- U-76,253 possesses broad-spectrum antimicrobial activity, with notable potency against common respiratory pathogens.
- The drug's efficacy is strain-dependent, highlighting the importance of susceptibility testing for certain bacterial groups.
- Further investigation into U-76,253's clinical utility is warranted based on its in vitro activity profile.